The National Health Insurance Administration (NHIA) yesterday announced that 18 types of medication, including 11 types of new drugs, are to be added to National Health Insurance (NHI) coverage, and that it is expected to benefit more than 14,000 patients.
According to a consensus reached by the Pharmaceutical Benefit and Reimbursement Scheme joint committee meeting held on Dec. 21 last year, three new drugs for treating cancer, three drugs for treating rare diseases and five other new drugs, as well as seven other drugs are to be covered by the NHI, the agency said.
The three new cancer drugs are abemaciclib, a targeted drug for the treatment of early-stage breast cancer, sacituzumab govitecan, a monoclonal antibody drug conjugate for treating triple-negative breast cancer, and polatuzumab vedotin, an antibody-drug conjugate for treating diffuse large B-cell lymphoma.
Photo: Chiu Chih-jou, Taipei Times
NHIA Medical Review and Pharmaceutical Benefits Division head Huang Yu-wen (黃育文) said adding abemaciclib as adjuvant therapy in early breast cancer patients with high risk of recurrence could reduce the risk of recurrence by 30 percent, and it is expected to benefit up to 2,150 people.
As there are few treatment options for triple-negative breast cancer, sacituzumab govitecan was included for patients who have received at least two sessions of systemic chemotherapy, but the tumor still has not been removed, no matter if they are a BRCA-mutant breast cancer patient or not, she said.
Although chemotherapy and stem cell transplantation is still the recommended treatment for diffuse large B-cell lymphoma patients, some patients cannot undergo a transplant nor chimeric antigen receptor T-cell therapy, so polatuzumab vedotin has been included to give them another option.
Other drugs for treating cancer that are to be covered include the dabrafenib-trametinib drug combination for treating patients with braf V600E-mutant advanced non-small cell lung cancer, and obinutuzumab for treating patient with chronic lymphocytic leukemia, the agency said.
They also include bevacizumab for the treatment of non-small cell lung cancer, ovarian cancer, fallopian tube cancer or peritoneal cancer; and ibrutinib for the treatment of chronic lymphocytic leukemia, it said.
Stiripentol for the treatment of seizures in people with Dravet syndrome and cannabidiol for the treatment of epilepsy related to Dravet syndrome or tuberous sclerosis complex were also approved, Huang said, adding that cannabidiol is a controlled drug that is recommended as a backup treatment option.
Apremilast oral tablets for the treatment of plaque psoriasis were also included, and compared with some other systemic therapies, they are considered less likely to cause liver injuries, which would be a safer option, she said.
The NHIA said the inclusion of the 18 types of medication into NHI coverage is expected to benefit more than 14,554 patients and that they would be available from next month at the earliest.
Additional reporting by CNA
‘REGRETTABLE’: TPP lawmaker Vivian Huang said that ‘we will continue to support Chairman Ko and defend his innocence’ as he was transferred to a detention facility The Taipei District Court yesterday ruled that Taiwan People’s Party (TPP) Chairman Ko Wen-je (柯文哲) be detained and held incommunicado over alleged corruption dating to his time as mayor of Taipei. The ruling reversed a decision by the court on Monday morning that Ko be released without bail. After prosecutors on Wednesday appealed the Monday decision, the High Court said that Ko had potentially been “actively involved” in the alleged corruption and ordered the district court to hold a second detention hearing. Ko did not speak to reporters upon his arrival at the district court at about 9:10am yesterday to attend a procedural
Thirty Taiwanese firms, led by Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and ASE Technology Holding Co (日月光投控), yesterday launched a silicon photonics industry alliance, aiming to accelerate the medium’s development and address the energy efficiency of artificial intelligence (AI) devices like data centers. As the world is ushering in a new AI era with tremendous demand for computing power and algorithms, energy consumption is emerging as a critical issue, TSMC vice president of integrated interconnect and packaging business C.K. Hsu (徐國晉) told a media briefing in Taipei. To solve this issue, it is essential to introduce silicon photonics and copackaged optics (CPO)
BACK IN THE NEIGHBORHOOD: The planned transit by the ‘Baden-Wuerttemberg’ and the ‘Frankfurt am Main’ would be the German Navy’s first passage since 2002 Two German warships are set to pass through the Taiwan Strait in the middle of this month, becoming the first German naval vessels to do so in 22 years, Der Spiegel reported on Saturday. Reuters last month reported that the warships, the frigate Baden-Wuerttemberg and the replenishment ship Frankfurt am Main, were awaiting orders from Berlin to sail the Strait, prompting a rebuke to Germany from Beijing. Der Spiegel cited unspecified sources as saying Beijing would not be formally notified of the German ships’ passage to emphasize that Berlin views the trip as normal. The German Federal Ministry of Defense declined to comment. While
The High Court yesterday overturned a Taipei District Court decision to release Taiwan People’s Party Chairman Ko Wen-je (柯文哲) and sent the case back to the lower court. The Taipei District Prosecutors’ Office on Saturday questioned Ko amid a probe into alleged corruption involving the Core Pacific City development project during his time as Taipei mayor. Core Pacific City, also known as Living Mall (京華城購物中心), was a shopping mall in Taipei’s Songshan District (松山) that has since been demolished. On Monday, the Taipei District Court granted a second motion by Ko’s attorney to release him without bail, a decision the prosecutors’ office appealed
RSS